CILcare is the only preclinical CRO focused solely on Hearing.
CILcare is located in France and Lexington, MA. With their partner CBSET, they evaluate the preclinical efficacy and safety of drugs, biological compounds, gene therapy, cell therapy and medical devices to treat hearing loss, tinnitus and otitis.
Why does working in Hearing require such special expertise?
Because the cochlea, which receives sound, is extremely difficult to target and the signals sent by its hair cells must be understood by the brain. CILcare is the only CRO that has the expertise to understand this complexity, and therefore works on identifying, developing and delivering the therapies which will protect or restore hair cells and neurons which make the system function.
CILcare provides a broad range of highly robust & validated pharmacological models to assess ear disorders. Based on extensive experience and scientific excellence, with state-of-the art facilities, and using the most advanced instrumentation and technology, CILcare provides customized studies to best address your requirements.
Tinnitus is a physical condition characterized by the perception of a “phantom” sound with no corresponding external stimulation. The physiopathology of tinnitus is caused by dysfunctions of the central nervous system and abnormalities in the inner ear.
Within Neuroservice’s Alliance, CILcare’s services include:
